Selected Grants
TARGET-GASTRO - GI-02 Pro00114153 Longitudinal, observational, non-interventional study of FDA-approved medications and other therapies used in usual clinical practice.
Clinical TrialPrincipal Investigator · Awarded by TARGET PharmaSolutions, Inc. · 2024 - 2038A PHASE 1, OPEN-LABEL, SINGLE-SEQUENCE STUDY TO EVALUATE POTENTIAL DISEASE-MEDIATED DRUG-DRUG INTERACTION WITH SELECTED CYTOCHROME P450 SUBSTRATES IN ADULT SUBJECTS WITH ACTIVE OSINOPHILIC ESOPHAGITIS RECEIVING CENDAKIMAB
Clinical TrialPrincipal Investigator · Awarded by Celgene International II Sarl · 2023 - 2027A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis. Celldex_CDX0159-08_Pro00112764
Clinical TrialPrincipal Investigator · Awarded by Celldex Therapeutics, Inc. · 2023 - 2026A PHASE 3, MULTI-CENTER, MULTI-NATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
Clinical TrialPrincipal Investigator · Awarded by Celgene International II Sarl · 2023 - 2026Pro00113649_R668-EGE-2213: A PHASE 2/3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC GASTRITIS WITH OR WITHOUT EOSINOPHILIC DUODENITIS
Clinical TrialPrincipal Investigator · Awarded by Regeneron Pharmaceuticals, Inc. · 2024 - 2026A PHASE 3, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION AND MAINTENANCE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2021 - 2025A Phase 3, Multicenter, Open-Label, Extension Study to Evaluate the Efficacy and Safety of AK002 in Patients That Were Previously Enrolled in AK002-016 or AK002-012 Studies and have Eosinophilic Gastritis and/or Eosinophilic Duodenitis
Clinical TrialPrincipal Investigator · Awarded by Allakos Inc. · 2021 - 2024A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis
Clinical TrialPrincipal Investigator · Awarded by Arena Pharmaceuticals, Inc. · 2021 - 2023A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Studyto Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Duodenitis who have an Inadequate Response with, Lost Response to, or
Clinical TrialPrincipal Investigator · Awarded by Allakos Inc. · 2021 - 2023A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients with Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Who Have an Inadequate R
Clinical TrialPrincipal Investigator · Awarded by Allakos Inc. · 2020 - 2023A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis
Clinical TrialPrincipal Investigator · Awarded by Allakos Inc. · 2020 - 2023Gastroenterology Artificial INtelligence System for Detecting Colorectal Polyps (The GAIN Study)
Clinical TrialPrincipal Investigator · Awarded by Verily Life Sciences, LLC · 2022 - 2023A PHASE 2A, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF IRL201104 IN ADULT PARTICIPANTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS (EOE)
Clinical TrialPrincipal Investigator · Awarded by Revolo Biotherapeutics · 2022 - 2023A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole
Clinical TrialPrincipal Investigator · Awarded by Phathom Pharmaceuticals, Inc. · 2020 - 2023A Novel Radiometry-Guided Ablation Catheter to Reliably Treat Barrett's Disease
ResearchCo Investigator · Awarded by Symple Surgical, Inc. · 2021 - 2023A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study toEvaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonop
Clinical TrialPrincipal Investigator · Awarded by Phathom Pharmaceuticals, Inc. · 2020 - 2023PREEMPT CRC: PREvention Employing a Multiomics Plasma-based Test for ColoRectal Cancer
ResearchPrincipal Investigator · Awarded by Freenome Holdings, Inc. · 2021 - 2023Eosinophilic Esophagitis (EoE)
ResearchCo Investigator · Awarded by Takeda Pharmaceutical Company Limited · 2020 - 2022A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients with Gastroesophageal Reflux Disease while receiving Proton Pump Inhibitors
Clinical TrialPrincipal Investigator · Awarded by Ironwood Pharmaceuticals, Inc. · 2018 - 2021External Relationships
- Allakos
- American Partnership for Eosinophilic Diseases (APFED)
- AstraZeneca
- Bristol Myers Squibb
- Merck
- Novo Nordisk
- Target RWE, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.